Literature DB >> 21798286

Distinct PGE2-responder and non-responder phenotypes in human mast cell populations: "all or nothing" enhancement of antigen-dependent mediator release.

Hye Sun Kuehn1, Mi-Yeon Jung, Michael A Beaven, Dean D Metcalfe, Alasdair M Gilfillan.   

Abstract

UNLABELLED: Reports indicate that prostaglandin (PG)E(2) markedly enhances antigen-mediated degranulation in mouse bone marrow-derived mast cells (BMMCs) but not in human mast cells (HuMCs). We have examined the underlying mechanism(s) for this disparity in HuMCs derived from the peripheral blood of multiple donors in addition to mouse BMMCs. HuMCs from half of these donors failed to respond to PGE(2) and the PGE(2) EP3 receptor agonist, sulprostone. However, HuMCs from the remaining donors and the LAD2 human MC line responded to PGE(2) and sulprostone with marked enhancement of antigen-mediated degranulation and IL-8 production in a similar manner to that observed in mouse BMMCs. The EP2 agonist, butaprost, failed to modulate antigen-mediated responses in any type of MCs. These distinct phenotypes could not be explained by differences in EP2 or EP3 expression nor by differences in the ability of PGE(2) to elevate levels of cAMP, a signal recognized to down-regulate mast cell activation. Moreover, both responder and non-responder HuMC populations exhibited similar activation of phosphatidylinositol 3-kinase, and MAP kinases. However, translocation of PLCγ(1) to the cell membrane and the associated calcium signal were enhanced only in the responder HuMC population indicating that the link between EP3 and PLCγ is impaired in the non-responder HuMCs.
CONCLUSIONS: These data provide a cautionary note for the translating of observations in the mouse to human mast cell-dependent disorders, but may also provide a basis for examining the effects of co-activating receptors in patients susceptible to allergic conditions. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21798286      PMCID: PMC3205336          DOI: 10.1016/j.imlet.2011.07.002

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  32 in total

Review 1.  The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling.

Authors:  Luke A J O'Neill; Andrew G Bowie
Journal:  Nat Rev Immunol       Date:  2007-05       Impact factor: 53.106

Review 2.  G protein-coupled receptors and the modification of FcepsilonRI-mediated mast cell activation.

Authors:  Hye Sun Kuehn; Alasdair M Gilfillan
Journal:  Immunol Lett       Date:  2007-09-18       Impact factor: 3.685

Review 3.  Development, migration, and survival of mast cells.

Authors:  Yoshimichi Okayama; Toshiaki Kawakami
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 4.  Targeting kit activation: a potential therapeutic approach in the treatment of allergic inflammation.

Authors:  Bettina M Jensen; Dean D Metcalfe; Alasdair M Gilfillan
Journal:  Inflamm Allergy Drug Targets       Date:  2007-03

5.  Kit- and Fc epsilonRI-induced differential phosphorylation of the transmembrane adaptor molecule NTAL/LAB/LAT2 allows flexibility in its scaffolding function in mast cells.

Authors:  Shoko Iwaki; Jiri Spicka; Christine Tkaczyk; Bettina M Jensen; Yasuko Furumoto; Nicolas Charles; Martina Kovarova; Juan Rivera; Vaclav Horejsi; Dean D Metcalfe; Alasdair M Gilfillan
Journal:  Cell Signal       Date:  2007-10-16       Impact factor: 4.315

Review 6.  The tyrosine kinase network regulating mast cell activation.

Authors:  Alasdair M Gilfillan; Juan Rivera
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

7.  Synergistic activation of phospholipases Cgamma and Cbeta: a novel mechanism for PI3K-independent enhancement of FcepsilonRI-induced mast cell mediator release.

Authors:  Hye Sun Kuehn; Michael A Beaven; Hong-Tao Ma; Mi-Sun Kim; Dean D Metcalfe; Alasdair M Gilfillan
Journal:  Cell Signal       Date:  2008-01-22       Impact factor: 4.315

8.  Our perception of the mast cell from Paul Ehrlich to now.

Authors:  Michael A Beaven
Journal:  Eur J Immunol       Date:  2009-01       Impact factor: 5.532

Review 9.  Mechanisms of mast cell signaling in anaphylaxis.

Authors:  Dean D Metcalfe; Richard D Peavy; Alasdair M Gilfillan
Journal:  J Allergy Clin Immunol       Date:  2009-10       Impact factor: 10.793

10.  The cytokine interleukin-33 mediates anaphylactic shock.

Authors:  Peter N Pushparaj; Hwee Kee Tay; Shiau Chen H'ng; Nick Pitman; Damo Xu; Andrew McKenzie; Foo Y Liew; Alirio J Melendez
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-08       Impact factor: 11.205

View more
  5 in total

1.  The role of P2Y(14) and other P2Y receptors in degranulation of human LAD2 mast cells.

Authors:  Zhan-Guo Gao; Qiang Wei; M P Suresh Jayasekara; Kenneth A Jacobson
Journal:  Purinergic Signal       Date:  2012-07-24       Impact factor: 3.765

Review 2.  Regulation of mast cell responses in health and disease.

Authors:  Alasdair M Gilfillan; Michael A Beaven
Journal:  Crit Rev Immunol       Date:  2011       Impact factor: 2.214

3.  E-prostanoid 2 receptors dampen mast cell degranulation via cAMP/PKA-mediated suppression of IgE-dependent signaling.

Authors:  Mariona Serra-Pages; Ana Olivera; Rosa Torres; César Picado; Fernando de Mora; Juan Rivera
Journal:  J Leukoc Biol       Date:  2012-08-02       Impact factor: 4.962

4.  Mast cell adenosine receptors function: a focus on the a3 adenosine receptor and inflammation.

Authors:  Noam Rudich; Katya Ravid; Ronit Sagi-Eisenberg
Journal:  Front Immunol       Date:  2012-06-04       Impact factor: 7.561

5.  Mast cell chemotaxis - chemoattractants and signaling pathways.

Authors:  Ivana Halova; Lubica Draberova; Petr Draber
Journal:  Front Immunol       Date:  2012-05-25       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.